Owens & Minor Launches ByramConnect Digital Health Platform for Diabetes and Other Chronic Health Conditions
Owens & Minor (NYSE: OMI) has launched ByramConnect, a digital health platform powered by the Welldoc App, exclusively for Byram Healthcare customers. The FDA-cleared class II software medical device is designed to help patients with type 1 or type 2 diabetes and associated chronic conditions.
The platform combines AI-driven digital health coaching, self-tracking, and clinical insights across six health dimensions. It integrates with various devices including blood glucose meters, CGMs, blood pressure monitors, and fitness trackers. Clinical studies have shown improvements in key metrics including reduced A1C, lower blood pressure, and reduced body weight.
Key features include personalized digital coaching, diet and nutrition support, GLP-1 medication management, health reporting with actionable insights, and mental wellbeing guidance. The service is available at no additional charge to Byram diabetes customers.
Owens & Minor (NYSE: OMI) ha lanciato ByramConnect, una piattaforma di salute digitale supportata dall'App Welldoc, esclusivamente per i clienti di Byram Healthcare. Il dispositivo medico software di classe II approvato dalla FDA è progettato per aiutare i pazienti con diabete di tipo 1 o tipo 2 e condizioni croniche associate.
La piattaforma combina coaching di salute digitale guidato dall'IA, auto-tracciamento e approfondimenti clinici in sei dimensioni della salute. Si integra con vari dispositivi, tra cui glucometri, CGM, monitor della pressione sanguigna e braccialetti fitness. Studi clinici hanno mostrato miglioramenti in metriche chiave come riduzione dell'A1C, abbassamento della pressione arteriosa e perdita di peso.
Le funzionalità principali includono coaching digitale personalizzato, supporto per dieta e nutrizione, gestione dei farmaci GLP-1, reportistica sanitaria con intuizioni praticabili e guida al benessere mentale. Il servizio è disponibile senza costi aggiuntivi per i clienti diabetici di Byram.
Owens & Minor (NYSE: OMI) ha lanzado ByramConnect, una plataforma de salud digital impulsada por la App Welldoc, exclusivamente para clientes de Byram Healthcare. El dispositivo médico de software de clase II aprobado por la FDA está diseñado para ayudar a pacientes con diabetes tipo 1 o tipo 2 y condiciones crónicas asociadas.
La plataforma combina coaching de salud digital impulsado por IA, auto seguimiento y perspectivas clínicas en seis dimensiones de salud. Se integra con varios dispositivos, incluidos medidores de glucosa en sangre, CGM, monitores de presión arterial y rastreadores de fitness. Los estudios clínicos han mostrado mejoras en métricas clave, incluyendo reducción de A1C, menor presión arterial y reducción de peso corporal.
Las características clave incluyen coaching digital personalizado, soporte para dieta y nutrición, gestión de medicamentos GLP-1, informes de salud con información accionable y orientación sobre bienestar mental. El servicio está disponible sin cargo adicional para los clientes diabéticos de Byram.
Owens & Minor (NYSE: OMI)는 Byram Healthcare 고객만을 위한 Welldoc 앱 기반의 디지털 헬스 플랫폼 ByramConnect를 출시했습니다. 이 FDA 승인 반 2등급 의료 소프트웨어 장치는 1형 또는 2형 당뇨병 및 관련 만성 질환을 가진 환자를 돕기 위해 설계되었습니다.
이 플랫폼은 AI 기반의 디지털 헬스 코칭, 자가 추적 및 6가지 건강 차원에 걸친 임상 통찰력을 결합합니다. 혈당계, CGM, 혈압 모니터 및 피트니스 트래커 등 다양한 장치와 통합됩니다. 임상 연구에서 A1C 감소, 혈압 낮추기 및 체중 감량 등의 주요 지표 개선이 나타났습니다.
주요 기능으로는 개인화된 디지털 코칭, 식단 및 영양 지원, GLP-1 약물 관리, 실용적인 통찰력을 제공하는 건강 보고서 및 정신적 웰빙 안내가 포함됩니다. 이 서비스는 Byram 당뇨병 고객에게 추가 요금 없이 제공됩니다.
Owens & Minor (NYSE: OMI) a lancé ByramConnect, une plateforme de santé numérique alimentée par l'application Welldoc, exclusivement pour les clients de Byram Healthcare. Le dispositif médical en logiciel de classe II approuvé par la FDA est conçu pour aider les patients atteints de diabète de type 1 ou de type 2 et de maladies chroniques associées.
La plateforme combine un coaching de santé numérique basé sur l'IA, un auto-suivi et des insights cliniques dans six dimensions de la santé. Elle s'intègre à divers appareils, y compris des mesureurs de glycémie, des CGM, des moniteurs de la pression artérielle et des trackers de fitness. Des études cliniques ont montré des améliorations dans des indicateurs clés comme une réduction de l'A1C, une pression sanguine plus basse et une réduction du poids.
Les fonctionnalités clés comprennent un coaching digital personnalisé, un soutien en matière de régime et de nutrition, la gestion des médicaments GLP-1, des rapports de santé avec des informations exploitables, et des conseils pour le bien-être mental. Ce service est disponible sans frais supplémentaires pour les clients diabétiques de Byram.
Owens & Minor (NYSE: OMI) hat ByramConnect, eine digitale Gesundheitsplattform, die von der Welldoc-App unterstützt wird, exklusiv für Byram Healthcare-Kunden eingeführt. Das von der FDA zugelassene medizinische Softwaregerät der Klasse II wurde entwickelt, um Patienten mit Typ-1- oder Typ-2-Diabetes und verwandten chronischen Erkrankungen zu helfen.
Die Plattform kombiniert KI-gesteuertes digitales Gesundheitscoaching, Selbstverfolgung und klinische Einblicke über sechs Gesundheitsdimensionen. Sie integriert sich mit verschiedenen Geräten, darunter Blutzuckermessgeräte, CGM, Blutdruckmessgeräte und Fitness-Tracker. Klinische Studien haben Verbesserungen bei Schlüsselmetriken gezeigt, darunter verringerter A1C, niedrigerer Blutdruck und Gewichtsreduktion.
Zu den Hauptfunktionen gehören personalisiertes digitales Coaching, Unterstützung bei Diät und Ernährung, GLP-1 Medikationsmanagement, Gesundheitsberichte mit umsetzbaren Erkenntnissen und Unterstützung für das psychische Wohlbefinden. Der Service ist für Byram-Diabetes-Kunden ohne zusätzliche Kosten verfügbar.
- FDA-cleared class II medical device status adds credibility and regulatory compliance
- Clinical studies demonstrate concrete health improvements in key metrics
- Free service for existing customers, potentially increasing customer retention
- Integration with multiple health monitoring devices enhances product utility
- to existing Byram Healthcare customers only, restricting market reach
Insights
The launch of ByramConnect marks a significant strategic evolution for Owens & Minor, positioning the company at the intersection of healthcare delivery and digital innovation. This FDA-cleared platform represents more than just a technological advancement - it's a calculated move to strengthen the company's competitive moat in the home healthcare sector.
The platform's integration with multiple data sources and devices creates a comprehensive ecosystem that could significantly increase customer stickiness and lifetime value. By offering the service exclusively to Byram customers at no additional cost, OMI is effectively building barriers to competition while potentially reducing customer churn - a critical factor in the highly competitive medical supply distribution market.
The timing of this launch is particularly strategic, coinciding with the rapid growth in GLP-1 medications and increasing focus on diabetes management. The platform's specific support for GLP-1 medication management positions OMI to capitalize on this expanding market segment. The clinical validation, showing improvements in A1C levels, blood pressure and body weight, adds credibility and could drive adoption among healthcare providers.
From a business perspective, while the platform is offered free to customers, the real value proposition lies in its potential to:
- Increase medical supply orders through better adherence tracking
- Reduce customer acquisition costs through improved retention
- Generate valuable health data that could be monetized (with appropriate privacy measures)
- Position OMI for value-based care partnerships with insurers
The platform's AI-driven capabilities and focus on six dimensions of health suggest scalability potential beyond diabetes, possibly extending to other chronic conditions. This could open new market opportunities and revenue streams for OMI in the growing digital health sector.
Now available as a free service exclusively to Byram Healthcare customers, ByramConnect powered by the Welldoc App combines digital health coaching, self-tracking, clinically relevant insights and education to support members with diabetes and associated chronic health conditions throughout their health journey.
The ByramConnect platform offers Byram diabetes customers access to the Welldoc App, which provides their care teams a holistic view of their condition by combining patient-tracked health data and connected sources such as fitness trackers, blood glucose meters, continuous glucose monitors (CGMs), blood pressure monitors, scales, heart rate monitors and medical labs and pharmacies. (Photo: Business Wire)
“Chronic health conditions like diabetes are complex and can have long-term health implications that require multiple supportive interventions over the course of a member’s care journey,” said Perry Bernocchi, EVP and CEO, Patient Direct, Owens & Minor. “We’re proud to offer Byram members a clinically validated platform designed to help them achieve concrete goals, such as weight management and improved control over their diabetes, in addition to longer-lasting behavior changes that help support a lifetime of better overall health.”
ByramConnect powered by the Welldoc App is a
Additional ByramConnect powered by the Welldoc App benefits include:
- Digital coaching: personalized, AI-driven digital coaching providing real-time feedback and coaching based on a patient’s unique data and trends
- Diet and nutrition support: tracking, insights and guidance to help promote healthy eating habits, including meal planning and restaurant recommendations based on dietary requirements
- GLP-1 medication support: support to help patients manage medications, monitor potential side-effects and track adherence over time
- Reporting & insights: health reports with actionable insights based on the patient’s unique data, patterns and trends that patients can share with their provider and care team
- Mental wellbeing: guidance and reinforcement to help members manage overall wellbeing, including mood, sleep and anxiety
*Welldoc Diabetes and Welldoc Diabetes Rx is an FDA-cleared medical device, intended for use by healthcare providers and their adult patients with type 1 or type 2 diabetes. For full labeling information, visit www.welldoc.com. The other Welldoc App products are non-FDA-cleared and intended to promote general wellness and education/self-management of various chronic disease states.
ByramConnect powered by the Welldoc App can be used on any device and is available now as an included service exclusively for Byram diabetes customers at no additional charge. Byram customers will receive an invitation via email within the next couple of weeks with an exclusive access code allowing them to download the app from the Apple or Google Play App stores. More information about ByramConnect powered by the Welldoc App can be found at byramhealthcare.com/byram-connect-powered-by-welldoc.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™.
For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.
*Registered Trademark or Trademark of O&M Halyard or its affiliates.
About Byram
Byram Healthcare (“Byram” or “Byram Healthcare Centers, Inc.”), part of the Owens & Minor family, delivers the products, services and support patients need to help improve health outcomes and affordability of care in the home. Along with Apria, Byram Healthcare makes up the Owens & Minor Patient Direct business segment, which serves nearly three million patients each year and offers one of the broadest portfolios of products for chronic and acute conditions including diabetes, wound care, sleep health, respiratory care, urology and ostomy care. For more information, visit byramhealthcare.com.
About Welldoc®
Welldoc, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc’s comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. The Welldoc App is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. For more information, visit www.welldoc.com.
| ______________ |
1. Quinn, et al. Diabetes Care (2011). |
2. Kumbara et al. Diabetes Technology (2022). |
3. Welldoc Data on File. |
4. CDC. Workplace Health Promotion (2022). |
OMI-CORP
OMI-IR
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211464037/en/
Media
Stacy Law, Owens & Minor
media@owens-minor.com
Source: Owens & Minor
FAQ
What are the key features of OMI's new ByramConnect platform?
How much does OMI's ByramConnect service cost for customers?
What clinical improvements have been shown with OMI's ByramConnect platform?
Which devices can integrate with OMI's ByramConnect platform?
What regulatory clearance does OMI's ByramConnect platform have?
